Certolizumab for axial spondylo- arthritis in Canada

Certolizumab for axial spondylo- arthritis in Canada

Health Canada has approved certolizumab pegol for the treatment of adults with severe active non-radiographic axial spondyloarthritis (nr-axSpA), UCB Canada Inc announced.

Certolizumab pegol is a pegylated monoclonal antibody against tumour necrosis factor-alpha (TNF-alpha).

Health Canada’s approval is based on data from C-AXSPAND5, a phase 3, multi-centre, double-blind, placebo-controlled 52-week study that randomised 317 adult patients to receive either certolizumab or placebo plus common background medications, which included NSAIDs, corticosteroids, analgesics and slow-acting anti-rheumatic drugs.

The US FDA approved certolizumab for the treatment of Crohn’s disease in people who did not respond sufficiently or adequately to standard therapy in 2015.

Straight Talk

View More